Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Market Research Future | PRODUCT CODE: 1268562

Cover Image

PUBLISHER: Market Research Future | PRODUCT CODE: 1268562

Preclinical CRO Market Forecast till 2030

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4950
PDF & Excel (Multi User License)
USD 5950
PDF & Excel (Enterprise License)
USD 7250

Add to Cart

Market Overview

The growth of the preclinical CRO market is expanding due to the R&D activities in the pharmaceutical and biotechnology sectors. As the demand for new drugs and therapies increases, pharmaceutical and biotech companies are allocating larger budgets for R&D to accelerate the drug development process. This includes outsourcing preclinical research activities to CROs, which offer specialized services and expertise in conducting preclinical studies to evaluate the safety and efficacy of new drug candidates.

Moreover, preclinical CROs provide cost-effective and time-efficient solutions for drug development compared to in-house research, as they offer access to state-of-the-art facilities, equipment, and expertise without the need for substantial investment in infrastructure and personnel. This cost-effective approach is especially appealing to smaller biotech companies and startups with limited resources, driving the demand for preclinical CRO services.

The demand for preclinical trials involving large molecules has also increased, and there is a need to reduce R&D expenses. Although the ongoing COVID-19 pandemic initially disrupted preclinical research projects, the development of lifesaving drugs has continued at a rapid pace. Additionally, the need to combat the spread of new viruses and infections and notable R&D initiatives in the healthcare sector is driving the market, globally. This industry's potential is also expected to increase due to the expected rise in the number of novel drugs entering the preclinical phase. Moreover, several pharmaceuticals and biotechnology companies are outsourcing preclinical validation programs to address medical needs, creating profitable opportunities for the market.

Segment Overview

he toxicology testing segment is expected to continue leading the growth in the preclinical CRO market, driven by the increasing demand for new drugs and chemicals. As drug development efforts continue to expand, toxicology testing plays a crucial role in evaluating the safety and potential adverse effects of new compounds, which is essential for regulatory approvals.

Additionally, the bioanalysis and DMPK segment is anticipated to grow in CAGR, as these services are essential for understanding the drug's metabolism, pharmacokinetics, and bioavailability. This information is critical in optimizing drug dosing regimens and ensuring their effectiveness in humans.

Moreover, oncology is expected to become the top segment in the near future, as cancer remains a significant global health challenge, and there is a high demand for novel oncology therapies. The increasing focus on precision medicine and targeted therapies for cancer treatment is driving the need for preclinical studies in oncology.

Furthermore, the pharmaceutical and biopharmaceutical sectors are predicted to be the key drivers of future growth in the preclinical CRO market. These sectors continue to invest in R&D to develop new drugs and therapies, and outsourcing preclinical studies to CROs allows them to streamline their drug development processes, reduce costs, and accelerate timelines.

Regional Analysis

North American region holds the biggest share of the preclinical CRO market as of 2021, mainly due to the presence of established CROs such as Charles River Laboratories and LabCorp that specialize in early drug discovery. The United States leads in outsourcing preclinical trials as many biopharmaceutical companies prefer to take advantage of the Investigational New Drug (IND) application approved by the FDA.

In the coming years, the Asia Pacific is expected to grow fastest growth in the preclinical CRO market due to changing business models of multinational corporations (MNCs) outsourcing and the increasing cost of research and development. The region is cost-efficient for outsourcing as it offers CROs located in countries such as India and China. Western European and U.S. based companies are also outsourcing analytical services, site research development, and clinical activities to the Asia Pacific region to reduce research-related costs.

Major Player

Envigo (U.S.), Eurofins Scientific (Luxembourg), Medpace (U.S.), Laboratory Corporation of America Holdings (U.S.), PRA Health Sciences (U.S.), D. Biosciences (U.S.), Charles River (U.S.), WuXi AppTec (China), and ICON PLC (Dublin), Pharmaceutical Product Development, LLC (U.S.), PAREXEL International Corporation (U.S.), IQVIA (U.S.) are among the companies operating in this market.

COVID 19, Impacts

The development of a COVID-19 vaccine and therapeutic treatments has led to a surge in demand for preclinical research services in this area, ongoing research projects have faced disruptions and delays due to compliance with social distancing regulations and temporary closures of research facilities and laboratories. Moreover, the economic uncertainty caused by the pandemic has resulted in reduced funding for some preclinical research projects, leading to a decline in demand for CRO services in certain sectors. However, demand for preclinical research in fields such as oncology, neurology, and cardiology has remained steady. In response to these challenges, the preclinical CRO market has embraced digital tools and virtual services, with remote monitoring, telemedicine, and virtual clinical trials becoming more common. This shift to digital platforms has enabled preclinical research to continue even amidst restrictions on physical laboratory access.

Product Code: MRFR/HC/5807-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION 16
  • 2.2 SCOPE OF THE STUDY 16
  • 2.3 MARKET STRUCTURE 16

3 RESEARCH METHODOLOGY

  • 3.1 RESEARCH PROCESS 17
  • 3.2 PRIMARY RESEARCH 18
  • 3.3 SECONDARY RESEARCH 18
  • 3.4 MARKET SIZE ESTIMATION 19
  • 3.5 FORECAST MODEL 20

4 MARKET DYNAMICS

  • 4.1 OVERVIEW 21
  • 4.2 DRIVERS 22
    • 4.2.1 GROWTH IN OUTSOURCING OF NON-CORE FUNCTIONS 22
    • 4.2.2 ENHANCED ABILITIES OF PRECLINICAL CROS TO OFFER ADDITIONAL VALUE-ADDED SERVICES 22
    • 4.2.3 SURGING NUMBER OF DRUGS IN THE PRECLINICAL PHASE 22
    • 4.2.4 ECONOMIES OF PRODUCTION AND SCALE 22
    • 4.2.5 MUTUAL BENEFIT TO THE CONTRACTOR AS WELL AS THE CLIENT 22
    • 4.2.6 HIGH R&D EXPENDITURE 23
  • 4.3 RESTRAINTS 24
    • 4.3.1 SCARCITY OF LABOUR AND HIGH LABOUR COST 24
    • 4.3.2 STRUCTURAL CHANGES IN THE INDUSTRY 24
  • 4.4 OPPORTUNITY 24
    • 4.4.1 OPPORTUNITY FOR MEDICAL DEVICE COMPANIES TO OUTSOURCE PRECLINICAL TRIALS TO CROS 24
  • 4.5 CHALLENGES 25
    • 4.5.1 SUPPLY CHAIN COMPLEXITY AND THIRD-PARTY CONTROL 25
    • 4.5.2 OUTDATED CLINICAL TRIAL ACTIVITIES 25
  • 4.6 MACROECONOMIC INDICATORS 25
  • 4.7 TRENDS 25

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS 26
    • 5.1.1 R&D 26
    • 5.1.2 GOOD LABORATORY PRACTICES (GLP) 26
    • 5.1.3 PRE-CLINICAL CRO TESTING 26
  • 5.2 PORTER'S FIVE FORCES ANALYSIS 27
    • 5.2.1 BARGAINING POWER OF SUPPLIERS 27
    • 5.2.2 BARGAINING POWER OF BUYERS 27
    • 5.2.3 THREAT OF NEW ENTRANTS 28
    • 5.2.4 THREAT OF SUBSTITUTES 28
    • 5.2.5 INTENSITY OF RIVALRY 28
  • 5.3 INVESTMENT OPPORTUNITIES 28
  • 5.4 PRICING ANALYSIS 28

6 PRECLINICAL CRO MARKET, BY SERVICE

  • 6.1 OVERVIEW 29
  • 6.2 TOXICOLOGY TESTING 31
  • 6.3 BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES 32
  • 6.4 OTHERS 33

7 PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

  • 7.1 OVERVIEW 34
  • 7.2 ONCOLOGY 36
  • 7.3 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 37
  • 7.4 CARDIOVASCULAR DISEASES 38
  • 7.5 IMMUNOLOGICAL DISORDERS 39
  • 7.6 RESPIRATORY DISEASES 40
  • 7.7 INFECTIOUS DISEASES 41
  • 7.8 DIABETES 42
  • 7.9 OTHERS 43

8 PRECLINICAL CRO MARKET, BY END USER

  • 8.1 OVERVIEW 44
  • 8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRIES 46
  • 8.3 MEDICAL DEVICE COMPANIES 47
  • 8.4 ACADEMIC INSTITUTES 48

9 GLOBAL PRECLINICAL CRO MARKET, BY REGION

  • 9.1 OVERVIEW 49
  • 9.2 AMERICAS 51

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.2.1 NORTH AMERICA 53

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.2.1.1 US 56

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.2.1.2 CANADA 57

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.2.2 LATIN AMERICA 59

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

  • 9.3 EUROPE 61

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.3.1 WESTERN EUROPE 63

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.3.1.1 GERMANY 66

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.3.1.2 FRANCE 67

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.3.1.3 UK 69

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.3.1.4 ITALY 70

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.3.1.5 SPAIN 72

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

      • 9.3.1.6 REST OF WESTERN EUROPE 73

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.3.2 EASTERN EUROPE 75

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

  • 9.4 ASIA-PACIFIC 77

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.4.1 JAPAN 80

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.4.2 CHINA 81

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.4.3 INDIA 83

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.4.4 AUSTRALIA 84

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.4.5 SOUTH KOREA 86

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.4.6 REST OF ASIA-PACIFIC 87

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

  • 9.5 MIDDLE EAST & AFRICA 89

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.5.1 MIDDLE EAST 91

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

    • 9.5.2 AFRICA 93

PRECLINICAL CRO MARKET, BY SERVICE

PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA

PRECLINICAL CRO MARKET, BY END USER

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION 95
  • 10.2 COMPANY SHARE ANALYSIS 95

11 COMPANY PROFILE

  • 11.1 IQVIA 99
    • 11.1.1 COMPANY OVERVIEW 99
    • 11.1.2 FINANCIAL OVERVIEW 99
    • 11.1.3 PRODUCTS/SERVICES OFFERED 100
    • 11.1.4 KEY DEVELOPMENTS 100
    • 11.1.5 SWOT ANALYSIS 101
    • 11.1.6 KEY STRATEGIES 101
  • 11.2 PAREXEL INTERNATIONAL CORPORATION 102
    • 11.2.1 COMPANY OVERVIEW 102
    • 11.2.2 FINANCIAL OVERVIEW 102
    • 11.2.3 PRODUCTS OFFERING 103
    • 11.2.4 KEY DEVELOPMENTS 103
    • 11.2.5 SWOT ANALYSIS 103
    • 11.2.6 KEY STRATEGIES 103
  • 11.3 ENVIGO 104
    • 11.3.1 COMPANY OVERVIEW 104
    • 11.3.2 FINANCIAL OVERVIEW 104
    • 11.3.3 PRODUCTS OFFERING 104
    • 11.3.4 KEY DEVELOPMENTS 104
    • 11.3.5 SWOT ANALYSIS 105
    • 11.3.6 KEY STRATEGIES 105
  • 11.4 CHARLES RIVER 106
    • 11.4.1 COMPANY OVERVIEW 106
    • 11.4.2 FINANCIAL OVERVIEW 106
    • 11.4.3 PRODUCTS/SERVICES OFFERED 106
    • 11.4.4 KEY DEVELOPMENTS 107
    • 11.4.5 SWOT ANALYSIS 107
    • 11.4.6 KEY STRATEGIES 107
  • 11.5 EUROFINS SCIENTIFIC 108
    • 11.5.1 COMPANY OVERVIEW 108
    • 11.5.2 FINANCIAL OVERVIEW 108
    • 11.5.3 PRODUCTS/SERVICES OFFERED 108
    • 11.5.4 KEY DEVELOPMENTS 109
    • 11.5.5 SWOT ANALYSIS 109
    • 11.5.6 KEY STRATEGIES 109
  • 11.6 ICON PLC 110
    • 11.6.1 COMPANY OVERVIEW 110
    • 11.6.2 FINANCIAL OVERVIEW 110
    • 11.6.3 PRODUCTS/SERVICES OFFERED 110
    • 11.6.4 KEY DEVELOPMENTS 111
    • 11.6.5 SWOT ANALYSIS 111
    • 11.6.6 KEY STRATEGIES 111
  • 11.7 PRA HEALTH SCIENCES (PRA) 112
    • 11.7.1 COMPANY OVERVIEW 112
    • 11.7.2 FINANCIAL OVERVIEW 112
    • 11.7.3 PRODUCTS/SERVICES OFFERED 112
    • 11.7.4 KEY DEVELOPMENTS 113
    • 11.7.5 SWOT ANALYSIS 113
    • 11.7.6 KEY STRATEGIES 113
  • 11.8 MEDPACE 114
    • 11.8.1 COMPANY OVERVIEW 114
    • 11.8.2 FINANCIAL OVERVIEW 114
    • 11.8.3 PRODUCTS/SERVICES OFFERED 114
    • 11.8.4 KEY DEVELOPMENTS 115
    • 11.8.5 SWOT ANALYSIS 115
    • 11.8.6 KEY STRATEGIES 115
  • 11.9 LABORATORY CORPORATION OF AMERICA HOLDINGS 116
    • 11.9.1 COMPANY OVERVIEW 116
    • 11.9.2 FINANCIAL OVERVIEW 116
    • 11.9.3 PRODUCTS/SERVICES OFFERED 117
    • 11.9.4 KEY DEVELOPMENTS 117
    • 11.9.5 SWOT ANALYSIS 117
    • 11.9.6 KEY STRATEGIES 117
  • 11.10 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 118
    • 11.10.1 COMPANY OVERVIEW 118
    • 11.10.2 FINANCIAL OVERVIEW 118
    • 11.10.3 PRODUCTS/SERVICES OFFERED 118
    • 11.10.4 KEY DEVELOPMENTS 118
    • 11.10.5 SWOT ANALYSIS 118
    • 11.10.6 KEY STRATEGIES 119
  • 11.11 WUXI APPTEC 120
    • 11.11.1 COMPANY OVERVIEW 120
    • 11.11.2 FINANCIAL OVERVIEW 120
    • 11.11.3 PRODUCTS/SERVICES OFFERED 120
    • 11.11.4 KEY DEVELOPMENTS 120
    • 11.11.5 SWOT ANALYSIS 121
    • 11.11.6 KEY STRATEGIES 121
  • 11.12 MD BIOSCIENCES 122
    • 11.12.1 COMPANY OVERVIEW 122
    • 11.12.2 FINANCIAL OVERVIEW 122
    • 11.12.3 PRODUCTS/SERVICES OFFERED 122
    • 11.12.4 KEY DEVELOPMENTS 122
    • 11.12.5 SWOT ANALYSIS 122
    • 11.12.6 KEY STRATEGIES 123

12 APPENDIX

  • 12.1 REFERENCES 124
  • 12.2 RELATED REPORTS 124
Product Code: MRFR/HC/5807-CR

LIST OF TABLES

  • TABLE 1 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 29
  • TABLE 2 GLOBAL PRECLINICAL CRO MARKET, FOR TOXICOLOGY TESTING, BY REGION, 2022-2030 (USD MILLION) 31
  • TABLE 3 GLOBAL PRECLINICAL CRO MARKET, FOR BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES, BY REGION, 2022-2030 (USD MILLION) 32
  • TABLE 4 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 33
  • TABLE 5 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 34
  • TABLE 6 GLOBAL PRECLINICAL CRO MARKET, FOR ONCOLOGY, BY REGION, 2022-2030 (USD MILLION) 36
  • TABLE 7 GLOBAL PRECLINICAL CRO MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2022-2030 (USD MILLION) 37
  • TABLE 8 GLOBAL PRECLINICAL CRO MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2030 (USD MILLION) 38
  • TABLE 9 GLOBAL PRECLINICAL CRO MARKET, FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022-2030 (USD MILLION) 39
  • TABLE 10 GLOBAL PRECLINICAL CRO MARKET, FOR RESPIRATORY DISEASES, BY REGION, 2022-2030 (USD MILLION) 40
  • TABLE 11 GLOBAL PRECLINICAL CRO MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2022-2030 (USD MILLION) 41
  • TABLE 12 GLOBAL PRECLINICAL CRO MARKET, FOR DIABETES, BY REGION, 2022-2030 (USD MILLION) 42
  • TABLE 13 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 43
  • TABLE 14 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 44
  • TABLE 15 GLOBAL PRECLINICAL CRO MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRIES, BY REGION, 2022-2030 (USD MILLION) 46
  • TABLE 16 GLOBAL PRECLINICAL CRO MARKET, FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022-2030 (USD MILLION) 47
  • TABLE 17 GLOBAL PRECLINICAL CRO MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 2022-2030 (USD MILLION) 48
  • TABLE 18 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 49
  • TABLE 19 GLOBAL PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 50
  • TABLE 20 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2022 & 2030 (USD MILLION) 50
  • TABLE 21 AMERICAS: PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 51
  • TABLE 22 AMERICAS: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 52
  • TABLE 23 AMERICAS: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 52
  • TABLE 24 AMERICAS: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 53
  • TABLE 25 NORTH AMERICA: PRECLINICAL CRO MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 53
  • TABLE 26 NORTH AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 54
  • TABLE 27 NORTH AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 55
  • TABLE 28 NORTH AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 55
  • TABLE 29 US: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 56
  • TABLE 30 US: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 56
  • TABLE 31 US: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 57
  • TABLE 32 CANADA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 57
  • TABLE 33 CANADA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 58
  • TABLE 34 CANADA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 58
  • TABLE 35 LATIN AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 59
  • TABLE 36 LATIN AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 59
  • TABLE 37 LATIN AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 60
  • TABLE 38 EUROPE: PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 61
  • TABLE 39 EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 62
  • TABLE 40 EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 62
  • TABLE 41 EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 63
  • TABLE 42 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 63
  • TABLE 43 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 64
  • TABLE 44 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 65
  • TABLE 45 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 65
  • TABLE 46 GERMANY: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 66
  • TABLE 47 GERMANY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 66
  • TABLE 48 GERMANY: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 67
  • TABLE 49 FRANCE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 67
  • TABLE 50 FRANCE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 68
  • TABLE 51 FRANCE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 68
  • TABLE 52 UK: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 69
  • TABLE 53 UK: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 69
  • TABLE 54 UK: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 70
  • TABLE 55 ITALY: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 70
  • TABLE 56 ITALY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 71
  • TABLE 57 ITALY: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 71
  • TABLE 58 SPAIN: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 72
  • TABLE 59 SPAIN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 72
  • TABLE 60 SPAIN: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 73
  • TABLE 61 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 73
  • TABLE 62 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 74
  • TABLE 63 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 74
  • TABLE 64 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 75
  • TABLE 65 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 75
  • TABLE 66 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 76
  • TABLE 67 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 77
  • TABLE 68 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 78
  • TABLE 69 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 79
  • TABLE 70 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 79
  • TABLE 71 JAPAN: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 80
  • TABLE 72 JAPAN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 80
  • TABLE 73 JAPAN: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 81
  • TABLE 74 CHINA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 81
  • TABLE 75 CHINA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 82
  • TABLE 76 CHINA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 82
  • TABLE 77 INDIA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 83
  • TABLE 78 INDIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 83
  • TABLE 79 INDIA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 84
  • TABLE 80 AUSTRALIA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 84
  • TABLE 81 AUSTRALIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 85
  • TABLE 82 AUSTRALIA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 85
  • TABLE 83 SOUTH KOREA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 86
  • TABLE 84 SOUTH KOREA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 86
  • TABLE 85 SOUTH KOREA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 87
  • TABLE 86 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 87
  • TABLE 87 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 88
  • TABLE 88 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 88
  • TABLE 89 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 89
  • TABLE 90 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 90
  • TABLE 91 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 90
  • TABLE 92 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 91
  • TABLE 93 MIDDLE EAST: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 91
  • TABLE 94 MIDDLE EAST: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 92
  • TABLE 95 MIDDLE EAST: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 92
  • TABLE 96 AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 93
  • TABLE 97 AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 93
  • TABLE 98 AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 94
  • TABLE 99 KEY DEVELOPMENTS & STRATEGIES 96

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS 15
  • FIGURE 2 GLOBAL PRECLINICAL CRO MARKET: MARKET STRUCTURE 16
  • FIGURE 3 RESEARCH PROCESS OF MRFR 17
  • FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH 20
  • FIGURE 5 MARKET DYNAMICS: GLOBAL PRECLINICAL CRO MARKET 21
  • FIGURE 6 VALUE CHAIN: GLOBAL PRECLINICAL CRO MARKET 26
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PRECLINICAL CRO MARKET 27
  • FIGURE 8 GLOBAL PRECLINICAL CRO MARKET SHARE, BY SERVICE, 2022 (%) 30
  • FIGURE 9 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2022 & 2030 (USD MILLION) 30
  • FIGURE 10 GLOBAL PRECLINICAL CRO MARKET SHARE, BY THERAPEUTIC AREA, 2022 (%) 35
  • FIGURE 11 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022 & 2030 (USD MILLION) 35
  • FIGURE 12 GLOBAL PRECLINICAL CRO MARKET SHARE, BY END USER, 2022 (%) 45
  • FIGURE 13 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2022 & 2030 (USD MILLION) 45
  • FIGURE 14 AMERICAS: PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 51
  • FIGURE 15 NORTH AMERICA: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2022 (%) 54
  • FIGURE 16 EUROPE: PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 61
  • FIGURE 17 WESTERN EUROPE: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2022 (%) 64
  • FIGURE 18 ASIA-PACIFIC: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2022 (%) 78
  • FIGURE 19 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 89
  • FIGURE 20 GLOBAL PRECLINICAL CRO MARKET SHARE ANALYSIS 2022 (%) 95
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!